[Skip to Content]
[Skip to Content Landing]
Research Letter
September 2018

Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non–Small Cell Lung Cancer

Author Affiliations
  • 1Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas
  • 2NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania
  • 3Sydney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 4Department of Radiation Oncology, Washington University in St Louis, St Louis, Missouri
  • 5Imaging and Radiation Oncology Core, Philadelphia, Pennsylvania
  • 6Division of Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee
JAMA Oncol. 2018;4(9):1287-1288. doi:10.1001/jamaoncol.2018.1258

In 2010, NRG Oncology published the initial results (3-year data) of their multicenter, single-arm, phase 2 NRG Oncology RTOG 0236 trial using sterotactic body radiation therapy (SBRT) to achieve a potent dose in patients with medically inoperable, clinically staged early lung cancer.1 Despite its rapid acceptance as a standard treatment, the implementation of SBRT into clinical practice has been incomplete.2 Patients enrolled in the NRG Oncology RTOG 0236 trial continued to be followed up per protocol for tumor control, toxic effects, and survival.3 In this report, we describe 5-year results specifically to understand how potential late events may influence the utility of SBRT for this frail population.